WASHINGTON, March 17,
2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc.
(Vanda) (Nasdaq: VNDA) today announced the appointment of Tage
Honoré, Ph.D., D.Sc. to its Board of Directors effective
March 15, 2023. Following Dr.
Honoré's appointment, Vanda's Board of Directors is now comprised
of six directors, five of whom are independent.
"Tage is a highly accomplished industry leader and respected
scientist with deep experience across a diverse range of
therapeutic areas," said Mihael H.
Polymeropoulos, M.D., Vanda's President, CEO and Chairman of
the Board. "We are confident that his scientific expertise and
executive experience will be invaluable, and look forward to
working with him as we continue to deliver innovative therapies for
patients."
Dr. Honoré currently serves as President of Aestus Partners LLC,
a business advisory firm with deep roots in the life sciences
sector. Previously, Dr. Honoré held executive leadership roles at
Novo Nordisk, Novartis and Purdue Pharma. In addition to his
executive accomplishments, Dr. Honoré is a distinguished
researcher, credited with discovering and naming the AMPA subtype
of Excitatory Amino Acid Receptors, as well as developing the AMPA
antagonists CNQX and NBQX, which have played a critical role in
advancing scientific understanding in this field. He is also the
author of over 100 peer-reviewed scientific articles.
Dr. Honoré received his MSc in Pharmaceutical Science, Ph.D. in
Medicinal Chemistry and D.Sc. in Neuropharmacology from the
University of Copenhagen.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on
the development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of patients.
For more on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com and follow us on Twitter @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this press release, including, without
limitation, statements regarding Dr. Honoré's ability to assist
Vanda in advancing its pipeline and product development and
achieving its business objectives, are "forward-looking statements"
under the securities laws. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. Forward-looking statements are based upon current
expectations that involve risks, changes in circumstances,
assumptions and uncertainties. Important factors that could cause
actual results to differ materially from those reflected in Vanda's
forward-looking statements include, among others, Vanda's
assumptions regarding its ability to complete the clinical
development and obtain regulatory approval for the products in its
pipeline. Therefore, no assurance can be given that the results or
developments anticipated by Vanda will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Vanda. Forward-looking statements
in this press release should be evaluated together with the various
risks and uncertainties that affect Vanda's business and market,
particularly those identified in the "Cautionary Note Regarding
Forward-Looking Statements", "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" sections of Vanda's Annual Report on Form 10-K for the
fiscal year ended December 31, 2022,
as updated by Vanda's subsequent Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and other filings with the U.S.
Securities and Exchange Commission, which are available at
www.sec.gov.
All written and verbal forward-looking statements attributable
to Vanda or any person acting on its behalf are expressly qualified
in their entirety by the cautionary statements contained or
referred to herein. Vanda cautions investors not to rely too
heavily on the forward-looking statements Vanda makes or that are
made on its behalf. The information in this press release is
provided only as of the date of this press release, and Vanda
undertakes no obligation, and specifically declines any obligation,
to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
Corporate Contact:
Kevin
Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original
content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-appoints-dr-tage-honore-to-its-board-of-directors-301774730.html
SOURCE Vanda Pharmaceuticals Inc.